In vitro activities of XXXX , @entity7143 , and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

@entity2379 @entity2380 @entity18203 @entity18873 @entity5627 @entity4895 @entity5074 @entity19323 @entity10057 @entity7143 @entity24135 @entity2059
We determined the in vitro susceptibilities of 314 strains of Candida spp., representing 13 species rarely isolated from blood, to @entity7143 and @entity5074 as well as four licensed systemic antifungal agents ( @entity2379 , @entity4895 , @entity2380 , and @entity2059 ). The organisms included 153 isolates of C. krusei, 67 isolates of @entity19323 , 48 isolates of @entity18203 , 10 isolates of C. famata, 10 isolates of C. kefyr, 6 isolates of C. pelliculosa, 5 isolates of @entity24135 , 4 isolates of @entity10057 , 3 isolates of @entity18873 , 3 isolates of C. inconspicua, 2 isolates of C. sake, and 1 isolate each of C. lambica, C. norvegensis, and C. zeylanoides. MIC determinations were made by the National Committee for Clinical Laboratory Standards reference broth microdilution method and Etest ( @entity2379 ). Resistance to both @entity2379 and @entity2380 was observed in strains of C. krusei, @entity19323 , @entity18203 , C. inconspicua, and C. sake. Resistance to @entity2379 , but not to @entity2380 , was also observed among isolates of C. kefyr and @entity24135 . @entity7143 and @entity5074 were active (MIC, < or = 1 micro g/ml) against 94 to 100% of these isolates. In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of @entity5074 . Continued surveillance will be necessary to detect the emergence of these species as more prevalent, resistant pathogens. The new @entity5627 appear to offer acceptable coverage of uncommon Candida sp. bloodstream infections.
